Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma.
BACKGROUND
The aim of this study was to examine the biodistribution of (131)I-herceptin in C3H/Bi mice with transplantable mammary adenocarcinoma with a high frequency of C-erbB2 receptor expression.


METHODS
Mice C3H/Bi with subcutaneously transplanted mammary adenocarcinoma were used as animal model to study the interaction between C-erbB2 receptor and hercepin, a humanized anti-C-erbB2 monoclonal antibody. The expression of the gene encoding C-erbB2 receptor in the tumours was studied by the RT-PCR technique.


RESULTS
Expression of this gene was found in 66% of the studied cases. Similarly, the presence of the C-erbB2 receptor in 77% of the tumours was detected by a Western blot analysis with the use of herceptin. Biodistribution experiments of iodine-labelled herceptin in mice C3H/Bi with adenocarcinoma revealed its maximal accumulation in the tumours at 48 hours since the i.v. injection (7% ID/g). The tumour/muscle radioactivity ratio reached its highest value (above 20) also at 48 hours after the injection.


CONCLUSIONS
C3H/Bi mice with this adenocarcinoma may be a good experimental model to study herceptin, or its fragments, labelled with different radionuclids for preliminary evaluation of their usefulness in the therapeutic and diagnostic aspects of breast cancer.
Wiercioch
Rafał
R
Department of Pharmaceutical Biochemistry, Molecular Biology Laboratory, Medical University, Łódź, Poland.
Balcerczak
Ewa
E
Byszewska
Ewa
E
Mirowski
Marek
M
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor / Q000378:metabolism*; D004195:Disease Models, Animal; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D007457:Iodine Radioisotopes / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D007553:Isotope Labeling / Q000379:methods; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000235:genetics / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D051379:Mice; D008809:Mice, Inbred C3H; D009928:Organ Specificity; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D014018:Tissue Distribution; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab